Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Meda acquires erectile dysfunction therapy Muse from Vivus

Oct. 6, 2010

Pfizer describes new antagonists of calcium-sensing CaS receptor

Oct. 6, 2010

Lipideon Biotechnology claims new cholesterol absorption inhibitors

Oct. 6, 2010

GW Pharma begins phase IIa trial of cannabinoids in type 2 diabetes

Oct. 5, 2010

Pierre Fabre Medicament discloses new 11-beta-HSD1 inhibitors

Oct. 5, 2010

Phase III trial of lixisenatide in combination with basal insulin meets primary endpoint

Oct. 4, 2010

FDA grants type B meeting to Repros to discuss phase III protocols for Androxal

Oct. 4, 2010

NNC-126-0083 is well tolerated in adults and children with growth hormone deficiency

Oct. 4, 2010

Conbriza is approved in Spain for postmenopausal osteoporosis

Oct. 1, 2010

Enrollment complete in phase IIa trial of XOMA-052 in type 2 diabetes

Oct. 1, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...